SCHEMBL2532037

SCHEMBL2532037

N#Cc1cc(-c2nc3cncnc3s2)ccc1Oc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
HPGD P15428 3/20 0.41
NPSR1 Q6W5P4 1/20 0.41
SCN9A Q15858 3/20 0.39
TNK2 Q07912 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
POLB P06746 1/20 0.38
XDH P47989 2/20 0.38
ABCC4 O15439 1/20 0.38
ABCB11 O95342 1/20 0.38
PGR P06401 1/20 0.38
CHRM1 P11229 1/20 0.38
PDE4A P27815 1/20 0.38
BLVRB P30043 1/20 0.38
TARBP2 Q15633 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
ABCG2 Q9UNQ0 1/20 0.38
KDM4E B2RXH2 3/20 0.38
HTT P42858 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4152592 0.91 ALDH1A1 (0.52) ALDH1A1HPGDNPSR1TNK2SMN1; SMN2
Hydrochloric Acid SCHEMBL4163294 0.90 ALDH1A1 (0.51) ALDH1A1HPGDNPSR1TNK2SMN1; SMN2
SCHEMBL4159263 0.90 SLC22A12 (0.41) ALDH1A1HPGDNPSR1SCN9AXDH
SCHEMBL4141873 0.90 ALDH1A1 (0.38) ALDH1A1HPGDNPSR1SCN9ASMN1; SMN2
SCHEMBL2535698 0.90 SLC22A12 (0.44) ALDH1A1HPGDNPSR1SCN9AKDM4E
SCHEMBL4146990 0.89 SLC22A12 (0.46) ALDH1A1HPGDNPSR1SCN9ASMN1; SMN2
SCHEMBL4154840 0.89 SLC22A12 (0.44) ALDH1A1HPGDNPSR1SCN9ASMN1; SMN2
Potassium SCHEMBL4146433 0.89 ALDH1A1 (0.37) ALDH1A1HPGDNPSR1SCN9ASMN1; SMN2
SCHEMBL4146427 0.89 ALDH1A1 (0.37) ALDH1A1HPGDNPSR1SCN9ASMN1; SMN2
SCHEMBL4300552 0.87 ALDH1A1 (0.36) ALDH1A1HPGDNPSR1SCN9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3263109-B1 DRUG FOR PREVENTING AND/OR TREATING DEMENTIA NAT UNIV CORP TOTTORI UNIV (JP) 2020-06-17 EP claimed
EP-3219319-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT Nippon Chemiphar Co., Ltd. (JP) 2017-09-20 EP claimed
EP-2036561-B1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT NIPPON CHEMIPHAR CO (JP) 2017-05-10 EP claimed
US-20110257201-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT NIPPON CHEMIPHAR CO., LTD. (JP) 2011-10-20 US claimed
US-20100234399-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT NIPPON CHEMIPHAR CO., LTD. (JP) 2010-09-16 US claimed
EP-2036561-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT Nippon Chemiphar Co., Ltd. (JP) 2009-03-18 EP claimed
EP-3263109-B1 DRUG FOR PREVENTING AND/OR TREATING DEMENTIA NAT UNIV CORP TOTTORI UNIV (JP) 2020-06-17 EP disclosed
US-10413546-B2 Drug for preventing and/or treating dementia NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY (JP) 2019-09-17 US disclosed
US-20180117047-A1 DRUG FOR PREVENTING AND/OR TREATING DEMENTIA NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY (JP) 2018-05-03 US disclosed
EP-3263109-A1 DRUG FOR PREVENTING AND/OR TREATING DEMENTIA National University Corporation Tottori University (JP) 2018-01-03 EP disclosed
EP-3219319-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT Nippon Chemiphar Co., Ltd. (JP) 2017-09-20 EP disclosed
EP-3219319-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT Nippon Chemiphar Co., Ltd. (JP) 2017-09-20 EP disclosed
EP-2036561-B1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT NIPPON CHEMIPHAR CO (JP) 2017-05-10 EP disclosed
US-20100234399-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT NIPPON CHEMIPHAR CO., LTD. (JP) 2010-09-16 US disclosed
CN-101505755-A Agent for overcoming resistance to anticancer drug NIPPON CHEMIPHAR CO (JP) 2009-08-12 CN disclosed
US-20090149452-A1 XANTHINE OXIDASE INHIBITOR NIPPON CHEMIPHAR CO., LTD. (JP) 2009-06-11 US disclosed
EP-2036561-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT Nippon Chemiphar Co., Ltd. (JP) 2009-03-18 EP disclosed
EP-2036561-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT Nippon Chemiphar Co., Ltd. (JP) 2009-03-18 EP disclosed
EP-1911760-A1 XANTHINE OXIDASE INHIBITOR Nippon Chemiphar Co., Ltd. (JP) 2008-04-16 EP disclosed
WO-2007148835-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT NIPPON CHEMIPHAR CO., LTD. (JP) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180117047-A1 DRUG FOR PREVENTING AND/OR TREATING DEMENTIA XDH, ACHE, DDO ALDH1A1 455/4885HPGD 34/4885NPSR1 1390/4885
US-20090149452-A1 XANTHINE OXIDASE INHIBITOR XDH, PNPO, CBR1 ALDH1A1 304/4885HPGD 143/4885NPSR1 751/4885
US-10413546-B2 Drug for preventing and/or treating dementia XDH, ACHE, DDO ALDH1A1 455/4885HPGD 34/4885NPSR1 1390/4885
US-20100234399-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT TMX1, TPX2, XDH ALDH1A1 1351/4885HPGD 386/4885NPSR1 4617/4885
US-20110257201-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT TMX1, TPX2, XDH ALDH1A1 1351/4885HPGD 386/4885NPSR1 4617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.